284 related articles for article (PubMed ID: 36060967)
1. Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure.
Gao Q; Ma C; Meng S; Wang G; Xing Q; Xu Y; He X; Wang T; Cao Y
Front Endocrinol (Lausanne); 2022; 13():946504. PubMed ID: 36060967
[TBL] [Abstract][Full Text] [Related]
2. Shared diagnostic genes and potential mechanism between PCOS and recurrent implantation failure revealed by integrated transcriptomic analysis and machine learning.
Chen W; Yang Q; Hu L; Wang M; Yang Z; Zeng X; Sun Y
Front Immunol; 2023; 14():1175384. PubMed ID: 37261354
[TBL] [Abstract][Full Text] [Related]
3. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
4. Identification of microRNAs and genes associated with hyperandrogenism in the follicular fluid of women with polycystic ovary syndrome.
Xue Y; Lv J; Xu P; Gu L; Cao J; Xu L; Xue K; Li Q
J Cell Biochem; 2018 May; 119(5):3913-3921. PubMed ID: 29193229
[TBL] [Abstract][Full Text] [Related]
5. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
Wu R; Wu C; Zhu B; Li J; Zhao W
Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
[No Abstract] [Full Text] [Related]
6. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovary syndrome: Identification of novel and hub biomarkers in the autophagy-associated mRNA-miRNA-lncRNA network.
Huang J; Huang B; Kong Y; Yang Y; Tian C; Chen L; Liao Y; Ma L
Front Endocrinol (Lausanne); 2022; 13():1032064. PubMed ID: 36523600
[TBL] [Abstract][Full Text] [Related]
8. Pathway and network-based analysis of genome-wide association studies and RT-PCR validation in polycystic ovary syndrome.
Shen H; Liang Z; Zheng S; Li X
Int J Mol Med; 2017 Nov; 40(5):1385-1396. PubMed ID: 28949383
[TBL] [Abstract][Full Text] [Related]
9. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
[TBL] [Abstract][Full Text] [Related]
10. Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.
Velazquez ME; Millan AL; Rojo M; Abruzzese GA; Cocucci SE; Iglesias Molli AE; Frechtel GD; Motta AB; Cerrone GE
Front Endocrinol (Lausanne); 2021; 12():604215. PubMed ID: 34054718
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of immune cells and hub genes alterations in recurrent implantation failure: A GEO data mining study.
Yu L; Wang L; Wang L; Yan S; Chen S; Xu Q; Su D; Wang X
Front Genet; 2022; 13():1094978. PubMed ID: 36699469
[No Abstract] [Full Text] [Related]
12. Microarray analysis of obese women with polycystic ovary syndrome for key gene screening, key pathway identification and drug prediction.
Wei L; Xin C; Wang W; Hao C
Gene; 2018 Jun; 661():85-94. PubMed ID: 29601948
[TBL] [Abstract][Full Text] [Related]
13. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.
O'Reilly MW; Taylor AE; Crabtree NJ; Hughes BA; Capper F; Crowley RK; Stewart PM; Tomlinson JW; Arlt W
J Clin Endocrinol Metab; 2014 Mar; 99(3):1027-36. PubMed ID: 24423344
[TBL] [Abstract][Full Text] [Related]
14. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome.
de Medeiros SF; Rodgers RJ; Norman RJ
Hum Reprod Update; 2021 Jun; 27(4):771-796. PubMed ID: 33764457
[TBL] [Abstract][Full Text] [Related]
15. Screening of potential biomarkers for polycystic ovary syndrome and identification of expression and immune characteristics.
Liu S; Zhao X; Meng Q; Li B
PLoS One; 2023; 18(10):e0293447. PubMed ID: 37883387
[TBL] [Abstract][Full Text] [Related]
16. Hyperandrogenism and Polycystic ovary syndrome: Effects in pregnancy and offspring development.
Abruzzese GA; Silva AF; Velazquez ME; Ferrer MJ; Motta AB
WIREs Mech Dis; 2022 Sep; 14(5):e1558. PubMed ID: 35475329
[TBL] [Abstract][Full Text] [Related]
17. Free androgen index and Irisin in polycystic ovary syndrome.
Li H; Xu X; Wang X; Liao X; Li L; Yang G; Gao L
J Endocrinol Invest; 2016 May; 39(5):549-56. PubMed ID: 26584566
[TBL] [Abstract][Full Text] [Related]
18. 3 CpG Methylation Biomarkers for the Diagnosis of Polycystic Ovary Syndrome (PCOS) in Blood Samples.
Xie L; Jiang X; Chen Y; Huang C; Chen Y; Liu G; Sun W; Zeng L; Lu R
Comb Chem High Throughput Screen; 2022; 25(8):1304-1313. PubMed ID: 34080962
[TBL] [Abstract][Full Text] [Related]
19. Effects of Androgen Excess-Related Metabolic Disturbances on Granulosa Cell Function and Follicular Development.
Liao B; Qi X; Yun C; Qiao J; Pang Y
Front Endocrinol (Lausanne); 2022; 13():815968. PubMed ID: 35237237
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel candidate biomarkers and immune infiltration in polycystic ovary syndrome.
Na Z; Guo W; Song J; Feng D; Fang Y; Li D
J Ovarian Res; 2022 Jul; 15(1):80. PubMed ID: 35794640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
